APP
NVAX icon

Avantax Planning Partners’s Novavax NVAX Stock Holding History

Avantax Planning Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14
Closed -$1K – 896
2018
Q3 		$1K Buy
+14
New +$394 ﹤0.01% 1421
2018
Q2 		– Sell
-14
Closed -$1K – 1054
2018
Q1 		$1K Buy
+14
New +$562 ﹤0.01% 1732

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avantax Planning Partners's NVAX Position: Q4 2018 in Review

Avantax Planning Partners sold out of Novavax (NVAX) in Q4 2018, closing a stake of 14 shares — an estimated $1K sold.

Avantax Planning Partners first reported a position in NVAX in Q1 2018 and held it in 2 quarters. The position peaked at $1K in Q3 2018. 167 funds tracked by Wall St. Rank hold NVAX as of Q4 2018.

  • Avantax Planning Partners reported no remaining Novavax position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 14 Novavax shares in Q4 2018, an estimated $1K.
  • Avantax Planning Partners first reported a position in Novavax in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Novavax position peaked at $1K in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Novavax as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.